Sartorius Stedim Biotech recorded significant, profitable growth in 2025, building on the recovery momentum that began in fiscal year 2024. This positive development was driven by the larger and higher‑margin recurring business with consumables for the manufacture of biopharmaceuticals. Compared with a moderate prior-year base that had still been partially impacted by the reduction of elevated customer inventories, this business saw strong growth. As expected, sales of bioprocess equipment and systems continued to decline due to industry‑wide investment restraint but showed increasing stabilization.

Group Business Development

Forecasts have been prepared based on historical information and are consistent with accounting policies. All forecast figures are based on constant currencies, as in past years. Management points out that the dynamics and volatilities in the industry have increased significantly in recent years. In addition, uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries as well as the trade policy framework conditions, are playing a greater role. This results in higher uncertainty when forecasting business figures.